NOVAREX Co.Ltd (194700) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NOVAREX Co.Ltd (194700) has a cash flow conversion efficiency ratio of 0.041x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.73 Billion ≈ $7.27 Million USD) by net assets (₩260.64 Billion ≈ $176.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NOVAREX Co.Ltd net asset quality index to measure how much of total assets are equity-financed.
NOVAREX Co.Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how NOVAREX Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 194700 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
NOVAREX Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NOVAREX Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leatec Fine Ceramics Co Ltd
TWO:6127
|
0.003x |
|
Biomm S.A
SA:BIOM3
|
-0.164x |
|
ES Cube Co. Ltd
KQ:050120
|
-0.025x |
|
ADTechnology Co.Ltd
KQ:200710
|
-0.090x |
|
DYNACOR GROUP INC.
F:OA5
|
0.011x |
|
Sajo Ind
KO:007160
|
-0.007x |
|
Perfect Corp.
NYSE:PERF
|
0.027x |
|
Venu Holding Corporation
NYSE MKT:VENU
|
0.065x |
Annual Cash Flow Conversion Efficiency for NOVAREX Co.Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of NOVAREX Co.Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 194700 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩254.64 Billion ≈ $172.57 Million |
₩16.65 Billion ≈ $11.28 Million |
0.065x | +8.25% |
| 2024-12-31 | ₩220.26 Billion ≈ $149.27 Million |
₩13.31 Billion ≈ $9.02 Million |
0.060x | -52.15% |
| 2023-12-31 | ₩200.42 Billion ≈ $135.82 Million |
₩25.30 Billion ≈ $17.15 Million |
0.126x | +13.88% |
| 2022-12-31 | ₩181.37 Billion ≈ $122.91 Million |
₩20.11 Billion ≈ $13.63 Million |
0.111x | -35.83% |
| 2021-12-31 | ₩139.67 Billion ≈ $94.65 Million |
₩24.13 Billion ≈ $16.35 Million |
0.173x | +22.84% |
| 2020-12-31 | ₩115.61 Billion ≈ $78.35 Million |
₩16.26 Billion ≈ $11.02 Million |
0.141x | +1093.29% |
| 2019-12-31 | ₩91.79 Billion ≈ $62.21 Million |
₩-1.30 Billion ≈ $-880.82K |
-0.014x | -115.01% |
| 2018-12-31 | ₩78.93 Billion ≈ $53.49 Million |
₩7.44 Billion ≈ $5.04 Million |
0.094x | -53.95% |
| 2017-12-31 | ₩51.88 Billion ≈ $35.16 Million |
₩10.62 Billion ≈ $7.20 Million |
0.205x | +23.86% |
| 2016-12-31 | ₩44.62 Billion ≈ $30.24 Million |
₩7.38 Billion ≈ $5.00 Million |
0.165x | -31.13% |
| 2015-12-31 | ₩36.31 Billion ≈ $24.61 Million |
₩8.72 Billion ≈ $5.91 Million |
0.240x | -- |
About NOVAREX Co.Ltd
NOVAREX Co.,Ltd. manufactures, wholesales, and retails health and functional foods in South Korea and internationally. It offers lactic acid bacteria, omega-3, icle time, eye health, diet, boswellia, and lutein and zeaxanthin, as well as vitamin and mineral products in the form of tablets, soft and hard capsules, powder, liquid, gel, and jellies. The company was formerly known as Health Science C… Read more